World's Best Scientists 2026 revealed!
Agneta Siegbahn

Agneta Siegbahn

D-Index & Metrics

Medicine

D-Index
100
Citations
42934
World Ranking
8196
National Ranking
164

Agneta Siegbahn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Agneta Siegbahn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 453 publications — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Agneta Siegbahn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Agneta Siegbahn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Agneta Siegbahn is affiliated with Uppsala University in Sweden and has a primary focus on research within the field of Medicine, with a particular emphasis on Cardiology and Cardiovascular Medicine. Their work spans various subfields including Molecular Biology, Rheumatology, Endocrinology, Diabetes and Metabolism, as well as Surgery.

The scientist's research covers multiple topics related to cardiovascular health and disease. Prominent areas include:

  • Atrial Fibrillation Management and Outcomes
  • Cardiac Fibrosis and Remodeling
  • GDF15 and Related Biomarkers
  • Antiplatelet Therapy and Cardiovascular Diseases
  • S100 Proteins and Annexins
  • Acute Myocardial Infarction Research
  • Heart Failure Treatment and Management

Recent publications by Agneta Siegbahn highlight this broad focus on cardiovascular disease mechanisms and biomarkers. Notable papers include:

  • Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study, 2021, PLoS Medicine
  • Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis, 2020, Cancer Research
  • Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome, 2021, JAMA Cardiology
  • Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation, 2020, Journal of the American Heart Association
  • Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy, 2020, Journal of the American Heart Association

In terms of collaboration, this scientist frequently works with several researchers, showing multiple coauthorships with:

  • Lars Wallentin
  • Johan Lindbäck
  • Ziad Hijazi
  • Christopher B. Granger
  • John H. Alexander

Their research outputs are published predominantly in highly specialized cardiovascular and medical journals. The most frequent venues for their papers include:

  • Journal of the American Heart Association
  • European Heart Journal
  • Circulation
  • Cardiovascular Research
  • Journal of Thrombosis and Haemostasis

The wide range of topics and publication platforms indicate an ongoing contribution to the understanding of cardiovascular disease, vascular biology, and related biomarker discovery.

Best Publications

  • Discovery and refinement of loci associated with lipid levels

    Cristen J. Willer;Ellen M. Schmidt;Sebanti Sengupta;Gina M. Peloso;Gina M. Peloso;Gina M. Peloso

  • Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.

    J Waltenberger;L Claesson-Welsh;A Siegbahn;M Shibuya

  • Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.

    Bertil Lindahl;Henrik Toss;Agneta Siegbahn;Per Venge

  • Large-scale association analysis identifies new risk loci for coronary artery disease

    Panos Deloukas;Stavroula Kanoni;Christina Willenborg;Martin Farrall

  • Common variants associated with plasma triglycerides and risk for coronary artery disease

    Ron Do;Cristen J. Willer;Ellen M. Schmidt;Sebanti Sengupta

  • N-Terminal Pro–Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV Substudy

    Stefan K. James;Bertil Lindahl;Agneta Siegbahn;Mats Stridsberg

  • Low-molecular-weight heparin during instability in coronary artery disease

    L Wallentin;J Ohlsson;E Swahn;E Karlsson

  • Relationship Between Interleukin 6 and Mortality in Patients With Unstable Coronary Artery Disease: Effects of an Early Invasive or Noninvasive Strategy

    Eva Lindmark;Erik Diderholm;Lars Wallentin;Agneta Siegbahn

  • Prognostic Influence of Increased Fibrinogen and C-Reactive Protein Levels in Unstable Coronary Artery Disease

    Henrik Toss;Bertil Lindahl;A Siegbahn;Lars Wallentin

  • Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

    Tomas Jernberg;Christopher D. Payne;Kenneth J. Winters;Christelle Darstein

  • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

    Jonas Oldgren;Andrzej Budaj;Christopher B. Granger;Yasser Khder

  • Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease.

    Raffaele De Caterina;Steen Husted;Lars Wallentin;Felicita Andreotti

  • Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

    Ziad Hijazi;Stefan H. Hohnloser;Jonas Oldgren;Ulrika Andersson

  • Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals

    Lasse Folkersen;Stefan Gustafsson;Qin Wang;Qin Wang;Daniel Hvidberg Hansen

  • The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

    Ziad Hijazi;Jonas Oldgren;Johan Lindbäck;John H Alexander

  • Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

    Ziad Hijazi;Jonas Oldgren;Ulrika Andersson;Stuart J. Connolly

  • Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

    Lars Wallentin;Christoph Varenhorst;Stefan James;David Erlinge

  • The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

    Ziad Hijazi;Johan Lindbäck;John H. Alexander;Michael Hanna

  • Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis.

    Peter Blume-Jensen;Lena Claesson-Welsh;Agneta Siegbahn;Krisztina M. Zsebo

  • PDGF alpha- and beta-receptors activate unique and common signal transduction pathways.

    A Eriksson;A Siegbahn;B Westermark;C H Heldin

Frequent Co-Authors

Lars Wallentin
Lars Wallentin Uppsala University
Stefan James
Stefan James Uppsala University
Robert F. Storey
Robert F. Storey University of Sheffield
Christopher B. Granger
Christopher B. Granger Duke University
Renato D. Lopes
Renato D. Lopes Duke University
Richard C. Becker
Richard C. Becker University of Cincinnati
John H. Alexander
John H. Alexander Duke University
Claes Held
Claes Held Uppsala University
Steen Husted
Steen Husted Aarhus University Hospital
Bertil Lindahl
Bertil Lindahl Uppsala University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, there are several flexible online degree options that can accelerate your career in healthcare. For those who want to advance quickly, accelerated dnp programs can help you earn a Doctor of Nursing Practice efficiently, paving the way for leadership roles.

Cost is an important factor for many students. That’s where cheapest dnp programs come in, helping you reach your career goals without a heavy financial burden. For those just starting out, online lpn programs offer a practical, entry-level path into nursing that can be completed quickly and conveniently.

If you already hold a BSN and are looking to specialize, consider bsn to np programs online, which allow you to advance into nurse practitioner roles in high-demand areas such as mental health. These related degrees and career pathways provide diverse, accessible routes for those passionate about healthcare to make a difference.

Best Scientists Citing Agneta Siegbahn

Trending Scientists

Recently Published Articles